DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HNSCC
Conditions
HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer, Lung Cancer, Urogenital Cancer
Trial Timeline
Jun 19, 2023 → Dec 31, 2026
NCT ID
NCT05902520About DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2
DP CD8 TIL + DP CD8 TIL KD + Low dose IL-2 is a phase 1 stage product being developed by Phio Pharmaceuticals for HNSCC. The current trial status is active. This product is registered under clinical trial identifier NCT05902520. Target conditions include HNSCC, Melanoma, Gynecologic Cancer.
What happened to similar drugs?
0 of 2 similar drugs in HNSCC were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
6
Activity
12
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05902520 | Phase 1 | Active |
Competing Products
18 competing products in HNSCC
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD2936 | AstraZeneca | Phase 2 | 42 |
| pepinemab + pembrolizumab | Merck | Phase 1/2 | 32 |
| Pembrolizumab | Merck | Phase 2 | 39 |
| Pembrolizumab, Cetuximab | Merck | Phase 2 | 35 |
| eftilagimod alpha + pembrolizumab (KEYTRUDA®) | Merck | Phase 2 | 35 |
| Cetuximab/avelumab | Merck | Phase 2 | 42 |
| Ulevostinag + Pembrolizumab | Merck | Phase 2 | 35 |
| Motolimod + Nivolumab | Bristol Myers Squibb | Phase 1 | 21 |
| Nivolumab + Cisplatin + Cetuximab | Bristol Myers Squibb | Phase 1 | 29 |
| Nivolumab + Relatlimab + Ipilimumab | Bristol Myers Squibb | Phase 2 | 42 |
| Ivonescimab 10 mg/kg + Ligufalimab + Pembrolizumab (KEYTRUDA ®) | Akeso | Phase 3 | 47 |
| FDC fianlimab+cemiplimab + Cemiplimab + Placebo | Regeneron Pharmaceuticals | Phase 2 | 42 |
| GTAEXS617 + SoC | Recursion Pharmaceuticals | Phase 1/2 | 33 |
| Ficerafusp alfa + Pembrolizumab | Bicara Therapeutics | Phase 2 | 36 |
| INBRX-106 + Pembrolizumab | Inhibrx Biosciences | Phase 2/3 | 39 |
| Tipifarnib + Alpelisib | Kura Oncology | Phase 1/2 | 26 |
| STRO-004 + Pembrolizumab | Sutro Biopharma | Phase 1 | 26 |
| Lymphoseek | Navidea Biopharmaceuticals | Phase 3 | 22 |